Product Description
Cetylpyridinium chloride, (CPC, CAS 123-03-5) as active ingredient of antiseptic oral mouthrinses has a broad antimicrobial spectrum with a rapid bactericidal effect on gram-positive pathogens and a fungicide effect on yeasts in particular. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/11505791/)
Mechanisms of Action: Cell Membrane Damager
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Hong Kong | Hungary | India | Ireland | Italy | Korea | Malaysia | Malta | Mexico | New Zealand | Norway | Pakistan | Peru | Philippines | Portugal | Russia | Serbia | Slovenia | South Africa | Spain | Taiwan | Turkey | United Arab Emirates | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Colgate Palmolive
Company Location: NEW YORK NY 10022
Company CEO: Noel R. Wallace
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Russia
Active Clinical Trial Count: 2
Highest Development Phases
Phase 1: Pharyngitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| GRM-01-07-2024 | P1 |
Recruiting |
Pharyngitis |
2026-12-01 |
|
| GRM-01-05-2024 | P1 |
Recruiting |
Pharyngitis |
2026-12-01 |